Optimization of medical therapy and specialist care for infl ammatory bowel disease (IBD) may reduce morbidity. We sought to characterize racial disparities in utilization of healthcare and medical therapy for IBD.
INTRODUCTION
Infl ammatory bowel disease (IBD), which comprises Crohn ' s disease (CD) and ulcerative colitis (UC), is a chronic and relapsing condition that substantially diminishes quality of life. Morbidity from IBD may be reduced by optimization of medical therapy. Among the goals of medical treatment is to minimize the prolonged use of corticosteroids through implementation of steroidsparing agents, such as immunomodulators and biologics, when clinically appropriate ( 1 ) . Tumor necrosis factor-α antagonists have been shown to be highly eff ective in achieving and maintaining steroid-free remission in both CD and UC. Th ese biological agents have additionally resulted in lower hospitalizations and surgery costs when judiciously implemented ( 2 -7 ) . Although biologics are considerably more expensive than other medications in the IBD armamentarium, they have been shown to be costeff ective when appropriately indicated ( 8 -11 ) .
Data from a recent retrospective study suggest that there may be racial disparities in the use of immunomodulator therapy and infl iximab for IBD, the fi rst biologic approved for use in CD and subsequently UC ( 12 ) . However, it was unclear whether the racial trends observed were independent of socioeconomic, health insurance, and income factors. Given the high costs associated with infl iximab therapy and widely published racial diff erences in socioeconomic status, the above factors may have been important contributors to disparities in medication use. Medication utilization may also be infl uenced by the expertise of the physician providing IBD care. Previous studies suggest that the medical management of IBD may be more optimized under the care of IBD specialists and tertiary referral centers ( 13, 14 ) .
To further characterize the potential determinants of health disparities in IBD, we have conducted a cross-sectional interview study with retrospective medical chart review to ascertain patterns of health-care utilization, specialist care, and medication utilization among black and white IBD patients seen at a tertiary referral center, while measuring important clinical and socioeconomic factors.
METHODS

Study population
All black IBD patients who have received care at the adult faculty outpatient gastroenterology clinics of Johns Hopkins Medical Institutions from IBD specialists have been invited to join a study of genetic risk factors for IBD, requiring completion of a phenotype questionnaire, including medication use, permission to access medical records for chart review, and blood withdrawal, beginning in October of 2003. On select clinic days beginning in 2005, the same recruitment specialist approached all white (as well as black) IBD patients to join a comparison study requiring completion of the same phenotype questionnaire including medication use, and permission to access medical records for chart review. Since 2005, black patients who have not wanted to participate in the genetic study have been given the option of joining the phenotype comparison study. All subjects had a confi rmed diagnosis of IBD by pathology, endoscopy, and medical records and were at least 18 years of age. All patients were asked if they would agree to be re-contacted for additional research studies regarding IBD. Both black and white IBD patients were contacted by telephone between October 2005 and December 2008, and those who agreed to participate were administered a health services and utilization questionnaire for this current study and comprised the study population.
Study protocol
Participants were contacted over the phone by a single interviewer who administered a 40 -45 min questionnaire that queried socioeconomic status (employment status, marital status, education, and income), access to healthcare, health insurance, utilization of ambulatory physician and specialist services, emergency room visits, and hospitalizations. Th e questionnaire also used validated scales to measure health-related quality of life (HRQL) and disease severity. Medical charts were reviewed to determine disease phenotype using the validated NIDDK IBD Genetics Consortium modifi cation of the Montreal Classifi cation as previously described ( 15, 16 ) . Medical chart review was also used to classify patients as having ever or never used thiopurines (azathioprine or 6-mercaptopurine), methotrexate, other immunomodulators, or infl iximab. Patients were also designated as having prolonged steroid use if they were on steroids for more than 3 months.
Study instruments
Utilization of health and physician services was ascertained by patient self-report during the telephone interview. Although subjects were recruited from our faculty clinic, they may have been seen as consultations and did not necessarily receive regular gastroenterology or IBD specialist care at our center. General HRQL was measured by the SF-12 version 2 and disease-specifi c HRQL by the Short Infl ammatory Bowel Disease Questionnaire (SIBDQ), an abbreviated validated version of the IBDQ ( 17 ) . For CD patients, disease severity was measured using the Chapel Hill Index, a validated self-report instrument, which is based on and correlates with the Crohn ' s Disease Activity Index ( 18 ) . Similarly, the Simple Colitis Clinical Activity Index was used to measure disease severity in UC ( 19 ) . For both continuous scales, higher values refl ected greater disease severity. Comorbidity was selfreported using a validated summary scale, the Self-Administered Comorbidity Questionnaire (SCQ) ( 20 ) .
Statistical analysis
All analyses were conducted using Stata 10.0 soft ware (StataCorp LP, College Station, TX). We used the unpaired Student ' s t -test or Mann -Whitney test, as appropriate, to compare diff erences in means of continuous variables and the χ 2 -statistic for difference in proportions. Th e outcomes of interest were utilization of: routine gastroenterologist and IBD specialist care, non-routine health services (emergency department (ED) visits and hospitalizations), immunomodulators, and biologic agents. We used multiple logistic regression to determine the independent associations between these outcomes and race while adjusting for age, age at diagnosis, sex, comorbidity, health insurance, income, and education while accounting for clustering at the physician level. For utilization of biologics, we restricted analyses to infl iximab and excluded other biologics (notably, adalimumab) from consideration. Only infl iximab was FDA approved for CD at the start of the study. Similarly, we restricted analysis of infl iximab to only CD as infl iximab was not approved for UC at the start of the study. In addition, we adjusted infl iximab for calendar year as its use in CD may have increased over time.
Ethics review
Th is study was approved by the Institutional Review Board at the Johns Hopkins Medical Institutions.
RESULTS
Demographic and clinical characteristics
Th e baseline demographic characteristics of the study population are shown in Table 1 , stratifi ed by race. Compared with whites, blacks had lower income and level of education. Th ey were also less likely to have private health insurance and be married. Table 2 shows clinical characteristics and disease phenotype among both races. Blacks with CD were more likely to have involvement of the upper gastrointestinal tract than whites (22 % vs. 12 % , P = 0.02), but were otherwise not diff erent with respect to disease location or behavior. Black UC patients were less likely
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to have extensive UC than whites (49 % vs. 72 % , P = 0.05). Th ere were neither racial diff erences in general or IBD-specifi c HRQL (with nearly identical mean SIBDQ scores) nor were there diff erences in disease severity as measured by the Chapel Hill Index for CD or Simple Colitis Clinical Activity Index for UC, suggesting that overall black and white IBD patients were well matched for disease severity and impact of disease at the time of the questionnaire administration.
Utilization of ambulatory specialist care
Blacks and whites reported essentially identical number of IBDrelated ambulatory clinic visits in the preceding 12 months (4.7 vs . 4.7 visits, P = 0.94), although blacks were less likely than whites to be seen by a gastroenterologist on a regular basis at least once a year (85 % vs. 93 % , P = 0.03). While 77 % of blacks reported regularly seeing a gastroenterologist who had a reputation as an IBD subspecialist (i.e., at least once a year), 92 % of whites did so ( P = 0.001). Similarly, a much lower proportion of blacks reported that an IBD specialist assumed primary responsibility for their IBD-related healthcare as compared with whites (46 % vs. 72 % , P < 0.0001). In contrast, however, a similar proportion of blacks and whites reported seeing a primary care physician on a regular annual basis (83 % vs. 79 % , P = 0.8). After adjustment for age, age at diagnosis, sex, comorbidity, health insurance payer, educational attainment, income, and prolonged steroid use, blacks were significantly less likely than whites to be seen regularly by a gastroenterologist (adjusted odds ratio (aOR) 0.43; 95 % confidence interval (CI): 0.25 -0.75) or an IBD specialist (aOR 0.37; 95 % CI: 0.22 -0.61).
However, the lower likelihood that primary responsibility of IBD care was assumed by an IBD specialist among blacks compared with whites was no longer statistically significant (aOR 0.34; 95 % CI: 0.10 -1.18). Independent of race, uninsured patients were also considerably less likely than privately insured patients to be seen at least annually by a gastroenterologist (aOR 0.20; 95 % CI: 0.05 -0.88) or an IBD specialist (aOR 0.29; 95 % CI: 0.14 -0.59). 
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Perceived barriers to access of ambulatory IBD healthcare Table 3 shows racially stratified patient perceptions of whether there was difficulty with scheduling clinic appointments, affording healthcare, worries over the cost of healthcare, excessive wait times, transportation to clinics, and obtaining referrals for IBD specialist care. Blacks more often than whites reported difficulty with obtaining specialist referrals (12 % vs . 5 % , P = 0.02) and concerns over healthcare-related costs (18 % vs . 7 % , P = 0.01).
Utilization of non-routine health services
Blacks experienced more than threefold the number of IBDrelated visits to the ED than whites over the preceding 12 months (1.4 vs . 0.4 ED visits, P = 0.0001), with the proportion of blacks who had at least one IBD-related visit to the ED in the previous 12 months nearly twofold higher than that of whites (40 % vs . 22 % , P = 0.001). Th e number of ED visits decreased with increasing quartile of income independent of race ( β -coeffi cient = − 0.26 visits / quartile, P = 0.01). Aft er multivariate adjustment for age, age at diagnosis, sex, comorbidity, health insurance payer, prolonged steroid use, educational attainment, and income, blacks were still twice as likely to have had at least one ED visit over 12 months than whites (aOR 2.02; 95 % CI: 1.22 -3.35). Income was an independent predictor of ED utilization with every incremental quartile of income being associated with a 31 % lower likelihood of having at least one ED visit (0.69; 95 % CI: 0.58 -0.81) as was age with every incremental decade associated with a 43 % decrease in odds of an ED visit (aOR 0.57; 95 % CI: 0.44 -0.75). Th ere were neither diff erences in average number of IBD-related hospitalizations between blacks and whites during the previous 12 months (0.8 vs. 0.5 hospitalizations, P = 0.10) nor was there a difference in the proportion of blacks and whites who required at least one hospitalization in the preceding 12 months (31 % vs . 26 % , P = 0.3; aOR 1.09; 95 % CI: 0.59 -2.01). Table 4 shows overall utilization of immunomodulators and infliximab and among clinical subgroups, stratifi ed by race. Utilization of immunomodulators was lower among blacks than whites (52 % vs . 68 % , P = 0.006), but this was only signifi cant among those with UC (38 % vs . 64 % , P = 0.009) and not those with CD (59 % vs. 70 % , P = 0.11). However, blacks were also less likely than whites to have ever received prolonged steroid use ( > 3 months) (72 % vs. 87 % , P = 0.003). When we restricted analyses to patients who required prolonged steroid use ( > 3 months), the proportions of black and white IBD patients who were taking immunomodulators were not statistically diff erent (67 % vs. 74 % , P = 0.24). Black CD patients were less likely than white CD patients to receive infliximab (41 % vs . 60 % , P = 0.01). Infl iximab use was not statistically diff erent between blacks and whites among CD patients with abdominal penetrating disease (43 % vs. 52 % , P = 0.6), perhaps considered as the most aggressive form of CD. Th ere was a more notable, but still nonsignifi cant trend toward lower infl iximab use among blacks in the subgroup of patients with perianal CD (48 % vs . 69 % , P = 0.12). Among the subgroup of CD patients with prolonged steroid use, infl iximab utilization was 20 % lower among blacks compared with white (47 % vs . 67 % , P = 0.02). Among CD patients with prolonged steroid use, the aOR for infl iximab use in blacks compared with whites was 0.41 (95 % CI: 0.21 -0.77) aft er adjustment for age, age at diagnosis, sex, comorbidity, type of health insurance, educational attainment, household income, and calendar year. In this same subgroup, there was no statistically signifi cant racial diff erence in the use of immunomodulators (aOR 0.87; 95 % CI: 0.48 -1.60) or any steroid-sparing agent (either an immunomodulator or infl iximab) (aOR 0.87; 95 % CI: 0.47 -1.61).
Utilization of immunomodulators and biologics
DISCUSSION
We have demonstrated racial disparities in the utilization of IBD specialist care, non-routine healthcare visits to the ED, and highcost medical therapies. Unlike previous studies that have reported disparities in IBD medical therapy but did not account for important socioeconomic and clinical confounders, our study also assessed factors such as income, educational attainment, HRQL, prolonged steroid use, and access to care. Th us, our fi ndings not only substantiate the presence of racial disparities in IBD, but also provide additional insight into some of their potential mechanisms. Furthermore, in addition to black race being a predictor classifi ed as insured, may still have greater need for ED services instead of outpatient care. It is possible that a physician ' s level of expertise in managing IBD may have a role in disparities in medication use. In this study, whites were more likely than blacks to be seen at least annually by a gastroenterologist or an IBD specialist. Th is racial diff erence was even more pronounced when we compared the proportion of patients who received most of their IBD-related healthcare by an IBD specialist. Th ese disparities in IBD specialist care remained evident even aft er adjusting for socioeconomic and clinical factors, including prolonged steroid use. Higher utilization of specialist vs. generalist care among whites compared with blacks has also been described for gastrointestinal endoscopic procedures ( 24 ) . Among the potentially contributing barriers to IBD specialist care are difficulties in obtaining specialist referrals and worries over health-care costs that were more oft en reported by blacks than whites in our study. Racial variations in referral patterns to specialists has been shown to be an important contributing factor to disparities in utilization of other health services, such as coronary angiography ( 25 ) . Geographic access may have a role in the observed disparities as well. A recent study has shown that communities in which blacks were clustered had correspondingly fewer gastroenterologists ( 26 ) . Our fi ndings of disparities in utilization of specialist care should also be construed in the context of an increasing shift of IBD care to primary care physicians. A recent study of a northern California health maintenance organization suggested a 25 -33 % decrease in ambulatory IBD visits to gastroenterologists and a greater than fourfold increase in visits to primary care physicians between 1998 and 2005 ( 27 ) . In contrast, there was an increase in the use of immunomodulators and infl iximab during the same time period. Th us, at least in a homogenously insured population, there is no clear correlation between trends in utilization of specialist care and IBD medical therapy.
Complementing the lower IBD specialist utilization in our population is our fi nding of a higher rate of emergency room visits among blacks compared with whites. Th is may be another manifestation of inequities in access to the health-care system. Th ough utilization of EDs may be an indication of urgent need for care, an estimated 85 % of ED visits are made for non-lifethreatening reasons ( 28 ) . Th ese may also be a refl ection of lack of access to ambulatory health services. As might have been expected, higher income, which would enable greater access to outpatient care, was associated with lower likelihood of ED visits. Interestingly, older age was also associated with fewer ED visits aft er adjustment for income, educational attainment, comorbidity, and health insurance or lack thereof. Th is fi nding may be explained by poor adherence to medical therapy and follow-up among younger individuals that arises from lesser maturity and acceptance of responsibility for chronic illness. Older individuals may also be more knowledgeable and experienced IBD patients, and therefore may do a better job with self-management of their disease. Even aft er accounting for the above predictors, blacks in our study were still almost twice as likely as whites to require at least one ED visit over the preceding 12 months. Th is fi nding cannot be explained by disease severity, as blacks had lower of higher utilization of emergency services, progressively lower household income was also a strong and independent factor. Our fi ndings were consistent with those of Flasar et al. ( 12 ) who similarly found a lower frequency of steroid, immunomodulator, and infl iximab use in blacks. Disease activity may be an important predictor of immunomodulator and infl iximab use, and chronic steroid use is considered by some as a surrogate indicator of disease severity. It is, however, an imperfect marker due to practice variations in the use of steroid-sparing agents, which is frequently suboptimal ( 21 ) . Despite fi nding higher prolonged steroid use among whites, we found no racial diff erences in other direct measures of disease severity or HRQL. We performed analyses that were restricted to subjects with prolonged steroid use because it is an appropriate indication for steroid-sparing agents ( 1 ) . In doing so, we found racial disparities in use of the more costly infl iximab, but not immunomodulators. Th ese racial diff erences were persistent even aft er multivariate adjustment for income and other confounders. It is interesting that while we found disparities in the use of infl iximab among CD patients with steroid dependence, no such inequities were noted in patients with abdominal penetrating disease. Th is fi nding may have been due to this subgroup analysis having being underpowered. Alternatively, as many practitioners consider abdominal penetrating disease the most aggressive and worrisome form of CD, racial disparities in the use of infl iximab in this group may be markedly narrowed to become insignifi cant. It may have also resulted from the availability of immunomodulators as an alternative to infl iximab therapy for the indication of steroid dependence, and, as such, the use of infl iximab was more discretionary. In contrast to our observations, a study from a Northern California health maintenance organization found no diff erence in utilization of infl iximab between blacks and whites IBD patients ( 22 ) . Th is inconsistency may be explained by health system-based diff erences in access to specialists and expensive medical therapies.
Our study expectedly showed decreased utilization of specialist care among uninsured individuals. Because only 9 % of whites and 24 % of blacks were insured by Medicare or Medicaid, our study may have been underpowered to detect diff erence in utilization between government-sponsored and private insurance programs. We should note that even though most of our study population was privately insured, these insurance programs are likely to be heterogenous with respect to co-pays and deductibles, fl exibility in choosing care providers, and types of specialist and procedural services and maximum benefi ts covered -factors which may additionally impact health utilization. Th ere may be systematic racial diff erences in types of health insurance programs that may engender diff erential access to specialist care. Our study ' s lack of detailed insurance data limits our ability to evaluate the independent or modifying contribution of the above insurance-related factors to racial disparities in health utilization. Similarly, the role of health insurance in racial disparities may have been obscured by our inability to diff erentiate between those who were adequately insured and those who were underinsured, the numbers of which have increased by 60 % in the United States between 2003 and 2007 ( 23 ) . Th e latter group, despite being
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Race and IBD Specialist Care prevalence of chronic steroid use and similar disease activity indices scores and number of hospitalizations.
Our study has several limitations, the most signifi cant of which is that the study population was recruited from a tertiary referral center. Th e prevalence of chronic steroid use is high and similar to that observed from other tertiary centers ( 12, 21 ) , which would support that these patients likely have greater disease severity than in a community setting. Th us, our results are not population-based and may not be generalizable to the entire IBD population or even other tertiary centers. Our study population is also a self-selective group, in which these individuals were able to access care at a tertiary referral center. Consequently, we may have underestimated the true extent of racial disparities in health-care utilization. Another limitation of the study is that the data, and especially that related to health utilization, were based on patient self-report. Because most of our subjects did not receive their care exclusively at Johns Hopkins and oft en the faculty gastroenterologist served as a consultant only, medical records from our institution could not reliably comprehensively ascertain health utilization. Although the extent of recall error would not be expected to vary by race, the possibility of recall bias still exists. However, other large survey-based studies of health utilization such as the National Health Interview Study (http: / / www.cdc. gov/nchs/about_nhis.htm ) have also relied on self-report.
Despite the above caveats, our study provides additional evidence of racial disparities in the fi eld of IBD that may impact the overall eff ectiveness of medical therapy. Clinical trials tout the potent efficacy of biologics, but these results were derived under ideal study conditions, in which minorities are underrepresented ( 29 -31 ) . Th e relatively lower utilization of specialist care and anti-tumor necrosis factor agents among blacks outside of a protocol-driven milieu may generate racial diff erences in how well the effi cacy of clinical trials is translated into real-world eff ectiveness. Th ese racial gaps may become increasingly relevant with growing evidence supporting the initiation of infl iximab early in the course of disease as a fi rst-or second-line agent ( 32, 33 ) . In addition to barriers to health-care access, the disparities observed from the studies may also arise from patient factors such as patient preferences and sociocultural beliefs. Future studies should delineate these potential contributions to healthcare and medication utilization. Meanwhile, the development of educational directives and guidelines may help to standardize indications for referrals to specialists and use of biological agents.
